|CALIXAR, the French biotech company specialized in the functional and native isolation / identification of complex therapeutic targets and antigens, announces the publication of new patent “leptospira immunoprotective proteins and methods of identification and use thereof” (WO 2016134373 A2). The invention, co-owned by Merial, Calixar, Genostar, Vetagro-Sup and Institut Pasteur, provides compositions and methods for eliciting heterologous protective immunity in animals against specific membrane proteins markers of Leptospiris virulence.|
The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars. This is the result of a 4-year ongoing collaborative work within the COVALEPT Consortium.
COVALEPT gathers a consortium of the following partners: Merial (coordinator), Calixar, Genostar, Vetagro-Sup, PX Therapeutics and Institut Pasteur.
The project aims at providing a leptospirosis vaccine candidate with canine and potentially multi-species application, using bioinformatics, molecular and biochemical tools allowing to accelerate the discovery and development of this specific target as well as other bacterial antigen targets (More information).